Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 314 | 51 | 261 |
| Samples | 131 | 30 | 99 |
| Peptides | 118 | 20 | 100 |
Function
BCCIP · BRCA2 and CDKN1A interacting protein
This gene product was isolated on the basis of its interaction with BRCA2 and p21 proteins. It is an evolutionarily conserved nuclear protein with multiple interacting domains. The N-terminal half shares moderate homology with regions of calmodulin and M-calpain, suggesting that it may also bind calcium. Functional studies indicate that this protein may be an important cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity via p21. This protein has also been implicated in the regulation of BRCA2 and RAD51 nuclear focus formation, double-strand break-induced homologous recombination, and cell cycle progression. Multiple transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 92 amino-acid changes on canonical ENST00000278100 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in BCCIP · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in BCCIP – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Hodgkins Lymphoma | 1/16 6% | 2/122 2% |
| Endometrial Carcinoma | 6/42 14% | 7/612 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 6/810 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Colorectal Carcinoma | 5/143 4% | 20/3239 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Bladder Carcinoma | 1/58 2% | 4/956 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 1/752 0% |
| Gastric Carcinoma | 1/74 1% | 6/1809 0% |
| Other Solid Cancers | 2/94 2% | 4/1515 0% |
| Melanoma | 0/210 0% | 7/1899 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 3/1390 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Biliary Tract Carcinoma | 1/54 2% | 1/950 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 3/2534 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 1/2640 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where BCCIP is mutated · all tissues, split by cell line vs tissue
How many mutations in BCCIP were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 314 mutations in BCCIP
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|